Drug Trial Radar · NCT04884035
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
224
Planned (sponsor's estimate)
Start
Sep 15, 2021
Primary completion
Dec 1, 2028
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- May 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 and/or CC-99282 and R-CHOP-21 combination has been defined.
Conditions
- Lymphoma, B-Cell
Interventions
CC-220Drug
CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
RituximabDrug
Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles
CyclophosphamideDrug
Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
DoxorubicinDrug
Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
VincristineDrug
Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
PrednisoneDrug
Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
CC-99282Drug
CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
Polatuzumab vedotinDrug
Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
RituximabDrug
Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) - Part 1Time frame: During the first 2 cycles of treatment (each cycle is 21 days)
- Recommended Phase 2 Dose (RP2D) - Part 1Time frame: During the first cycle of treatment (each cycle is 21 days)
- Safety and tolerability of CC-220 and CC-99282 at RP2D - Part 2Time frame: From the first dose of any IP until 28 days after the last dose of IP
- Maximum Tolerated Dose (MTD) - Part 2ATime frame: During the first cycle of treatment (each cycle is 21 days)
- Recommended Phase 2 Dose (RP2D) - Part 2ATime frame: During the first cycle of treatment (each cycle is 21 days)
Locations
36 sites in 7 countries. Site status is shown where the registry gives one.
Local Institution - 162
Birmingham, Alabama
Local Institution - 154
Scottsdale, Arizona
Local Institution - 169
Duarte, California
Local Institution - 160
Jacksonville, Florida
Local Institution - 161
Marietta, Georgia
Local Institution - 159
Kansas City, Kansas
Local Institution - 166
Wichita, Kansas
Local Institution - 152
Rochester, Minnesota
Local Institution - 163
Saint Louis Park, Minnesota
Local Institution - 151
Omaha, Nebraska
Local Institution - 170
Charlotte, North Carolina
Local Institution - 164
Winston-Salem, North Carolina
Local Institution - 155
Houston, Texas
Local Institution - 168
Murray, Utah
Local Institution - 171
St. George, Utah
Local Institution - 503
Perth, Australia
Local Institution - 501
Adelaide, South Australia, Australia
Local Institution - 702
Athens, Greece
Local Institution - 704
Athens, Greece
Local Institution - 701
Athens, Greece
Local Institution - 700
Thessaloniki, Greece
Local Institution - 601
Gdansk, Poland
Local Institution - 600
Krakow, Poland
Local Institution - 603
Słomniki, Poland
Local Institution - 602
Warsaw, Poland
Local Institution - 604
Wroclaw, Poland
Local Institution - 605
Skórzewo, Greater Poland Voivodeship, Poland
Local Institution - 300
Seoul, South Korea
Local Institution - 302
Seoul, South Korea
Local Institution - 301
Seoul, South Korea
Local Institution - 201
Barcelona, Spain
Local Institution - 203
Málaga, Spain
Local Institution - 200
Salamanca, Spain
Local Institution - 403
Taichung, Taiwan
Local Institution - 402
Taichung, Taiwan
Local Institution - 400
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.